Search Browse Earnings

Can-Fite BioPharma Ltd.

NYSE:CANF

Pharmaceutical Preparations·RAMAT GAN, L3

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Can-Fite BioPharma Ltd. — SlamSEC

Revenue

$810,000

+6.2% YoY

FY 2024

Adj. EBITDA

-$10.1M

-1244.9% margin

FY 2024

Net Income

-$10.2M

-1255.9% margin

FY 2024

EPS (Diluted)

-$0.01

FY 2024

Stock Price

$4.55

-1.1%

2026-03-06

52W Range

$3.36 – $46.60

P/E Ratio

-455.0x

Market Cap

$13.6B

Cash

$4.3M

FY 2024

Total Debt

—

Net Cash

$4.3M

FY 2024

Enterprise Value

$13.6B

Debt / EBITDA

0.4x

FY 2024

EV / EBITDA

-1345.6x

Employees

—